French

Acasti Pharma Inc.

  • English
  • About Us
    • Management
    • Board of Directors
    • Scientific Advisory Board
  • Clinical Pipeline
    • GTX-104
    • GTX-102
    • GTX-101
  • Investor Relations
    • Overview
    • News / Events
    • Company Info
    • Financial Results
    • Stock Data
    • Regulatory Filings
    • Governance
  • Newsroom
  • Careers
  • Contact
  • French

Press Releases

Investor Relations

Investor Relations

  • Overview
  • News / Events
    • Overview
    • Press Releases
    • Media
    • IR Calendar
    • Email Alerts
    • Grace Merger Conference Call
  • Company Info
    • Overview
    • Presentations
    • Contacts
    • FAQ
  • Financial Results
  • Stock Data
    • NASDAQ: ACST
    • TSXV: ACST
  • Regulatory Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Section 16 Filings
    • SEDAR
    • Tax Notifications
  • Governance
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News / Events

  • Overview
  • Press Releases
  • Media
  • IR Calendar
  • Email Alerts
  • Grace Merger Conference Call

Acasti Pharma Announces Publication of CaPre Bioavailability Study in Leading Peer-Reviewed Journal

Apr 1, 2019

Acasti Pharma to Present at the 2019 Spring Investor Summit in New York City on April 2nd

Mar 26, 2019

Acasti Pharma to Present at the Oppenheimer 29th Annual Healthcare Conference on March 19th

Mar 13, 2019

Acasti Pharma Recognized in TSX Venture Exchange’s 2019 Venture 50

Feb 21, 2019

Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019

Feb 14, 2019

Acasti Pharma Schedules Third Quarter Fiscal 2019 Conference Call

Feb 8, 2019

Acasti Pharma Awarded Broad Composition-of-Matter and Method of Use Patents by the European Patent Office

Jan 9, 2019

Acasti Pharma Announces TRILOGY Phase 3 Trials of CaPre® in Patients with Severe Hypertriglyceridemia Has Now Exceeded 65% Randomization, and More Than 100 Patients (>20%) Have Completed Their 6 Month Treatment Plan

Dec 31, 2018

Acasti Pharma Achieves Planned Enrollment Targets for TRILOGY Phase 3 Trials of CaPre® in Patients with Severe Hypertriglyceridemia

Dec 20, 2018

Acasti Pharma Provides Business Update for Second Quarter of Fiscal 2019

Nov 14, 2018
RSS
  • Prev
    • 1...
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • 13
    • ...23
    Next
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed
    © 2022 Acasti Pharma Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap